SBIR-STTR Award

Elisas for islet cell autoimmunity and prediabetes
Award last edited on: 12/16/2014

Sponsored Program
SBIR
Awarding Agency
NIH : NIDDK
Total Award Amount
$46,000
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Aristo Wojdani

Company Information

Allergy Immunology Technologies Inc (AKA: Allergy Immuno Technologies, Inc)

1527 Monrovia Avenue
Newport Beach, CA 92663
   (949) 645-3703
   N/A
   www.allergyimmuno.com
Location: Single
Congr. District: 48
County: Orange

Phase I

Contract Number: 1R43DK039293-01A1
Start Date: 5/1/1988    Completed: 10/31/1988
Phase I year
1988
Phase I Amount
$46,000
Strong evidence has accumulated to suggest that insulin-dependent diabetes is the result of autoantibodies against insulin and/or subcellular components of the cells of the islet of langerhans. Detection of these autoantibodies will give prior knowledge of the disease in order that preventive measures can be taken to avert or delay the disease. In phase fractions from purchased semi-synthetic human insulin, islet cells from porcine, bovine and human sources will be isolated, viz., plasma membrane enriched fraction, mixed secretory granules, mitochondria and the endoplasmic reticulum enriched fraction. The same subcellula fractions will be isolated from insulinoma cell lines. Pure insulin and each fraction from each source will be bound to solid phase matrices. Precharacterized, standard sera containing anti-islet autoantibodies from diabetic patients will be incubated together with matrix-bound fractions to react with specific component (s). Enzyme-bound anti-human igg will be added to detect antigen-bound antibodies. This procedure will determine the fractions containing the specific antigens against which autoantibodies are directed and establish the feasibility of elisa for the quantification of anti-insulin and anti-islet cell antibodies. Absolute specificity can be assured by purification of the islet cellglycoproteins and glycolipids to homogeneity by affinity chromatography. In phase ii, monoclonal antibodies against these specific and reactive (with human diabetes serum) fractions will be prepared. These antibodies will be used for affinity purification of large amounts of these antigens to be used for further development of both a rapid, dipstick screening test and an accurate quantitative elisa test for clinical trials

Thesaurus Terms:
Diagnostic Tests, Design, Development And Evaluation Of Diagnostic Tests, Human, Human Tissues, Fluids Etc. From Non-Related Sources Outside Immedia, Immunological Tests And Immunoassay, Enzyme-Linked Immunosorbent Assay (El, Immunology, Antigens, Surface Antigens, Immunopathology, Autoantibodies, Immunopathology, Autoimmune Disorders, Metabolic Disorders Diagnosis, Pancreas Hormones, Insulin, Pancreatic Islets, Physical Separation, Chromatography, Affinity, Pregnancy, Embryo-FetusNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----